Zacks Investment Research upgraded shares of Clinigen Group Plc (NASDAQ:CLIGF) from a hold rating to a buy rating in a report issued on Tuesday morning. They currently have $14.00 price objective on the stock.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Clinigen Group Plc (NASDAQ CLIGF) opened at 12.95 on Tuesday. Clinigen Group Plc has a 52-week low of $8.50 and a 52-week high of $13.00. The firm has a market cap of $1.49 billion and a PE ratio of 79.45.
WARNING: This piece was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/23/clinigen-group-plc-cligf-upgraded-to-buy-by-zacks-investment-research.html.
Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.
